Acadia Pharmaceuticals, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Acadia Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Acadia Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize small molecule drugs for the treatment of central nervous system disorders.It has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma both in collaboration with Allergan Inc and ACP-106 in IND-track development. The Group currently developing a portfolio consisting of four most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis and retained worldwide commercialization rights to pimavanserin. It operates in the United States and Europe.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report